Hepatitis D pathophysiology

Jump to navigation Jump to search

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D pathophysiology

CDC on Hepatitis D pathophysiology

Hepatitis D pathophysiology in the news

Blogs on Hepatitis D pathophysiology

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Jolanta Marszalek, M.D. [2] João André Alves Silva, M.D. [3]

Overview

Despite the limited knowledge concerning the pathogenesis of hepatitis delta virus (HDV) infection, the adaptive and innate immune systems are thought to play a pivotal role on hepatocellular injury. HDV requires the presence of HBV to be able to cause infection. Pathological changes in HDV are limited to the liver, the only organ in which HDV can replicate. Hepatitis B virus (HBV) is an essential co-factor in the evolution of hepatocellular damage, and infection with both HBV and HDV leads to more severe liver injury than HBV infection alone. There is evidence supporting the possibility that the virus can be cytopathic in certain genotypes. HDV is transmitted percutaneously, sexually, or through contact with infected blood or blood products. In rare occasions transmission may be perinatal. The different genotypes will influence viral assembly, and consequently infectivity.

Pathogenesis

Studies demonstrate that both the adaptive and innate immune systems may play an important role in liver injury and clearance of the virus, although these immune responses are poorly defined. Evidence points to an association between the quantity and quality of host T-cell responses and the level of infection control.[1] HDV appears to subvert the adaptive immune system away from Th-1 biased CD4 and CD8 T-cell response, a necessary process for viral clearance.

Hepatitis B virus (HBV) is an essential co-factor in the evolution of hepatocellular damage, and infection with both HBV and HDV leads to more severe liver injury than HBV infection alone. The mechanisms determining whether a person will spontaneously clear HDV, become chronically infected, or rapidly progress to hepatic fibrosis are not yet fully understood.[2] The fluctuating viral load of both HDV and HBV in different stages of infection may signify a direct association with the pathogenesis of disease progression. Studies have shown that during the acute phase of HDV infection, HDV viremia is associated with an increased level of alanine transaminase (ALT) and suppressed HBV. In the later stages of the chronic phase, HDV RNA decreases, HBV reactivates, and levels of transaminases are moderately elevated. At this point, either HDV or HBV replicate and lead to cirrhosis and hepatocellular carcinoma(HCC) or both viruses are cleared and there is remission. [2]

HDV suppresses HBV replication among patients with either coinfection or superinfection. In fact, up to 90% of patients with HDV coinfection are HBeAg negative and have a low HBV viral load. Furthermore, once HDV infection is cleared, replication of HBV can reactivate.[2] Evidence points to the possible role of the small(p24) and large(p27) HDV proteins in suppressing HBV replication by:[3]

  • Repressing the activity of two enhancer regions (pIIE1 and pIIE2)in the HBV genome
  • Transactivation of the MxA gene leading to the reduction of viral HBV mRNA export from the nucleus

Although hepatitis D is thought to be a largely immune-mediated disease process, there is evidence demonstrating that HDV may be cytopathic. Specifically, outbreaks of fulminant hepatitis induced by HDV genotype 3 link uncommon histological features to the potentially cytopathic nature of HDV.[4] More data is necessary to further the understanding of underlying mechanisms of HDV-induced disease.[2]

Transmission

HDV is transmitted percutaneously, sexually, or through contact with infected blood or blood products. Perinatal transmission is possible but uncommon. Blood is potentially infectious during all phases of active hepatitis D infection and a very small inoculum is sufficient to transmit HDV infection. Peak infectivity probably occurs just before the onset of acute disease. [5]

Genotype and Pathogenesis

The HDV genotype influences the sequence of the C-terminal moiety of the large HDAg. These changes in the C-terminal moiety will influence the packaging ability of the virus, which will ultimately dictate interaction with clathrin and consequently the efficiency of viral assembly and infectivity.[6][7][8] The fact that all genotypes are able to bind clathrin supports the importance of clathrin in HDV assembly.[9]

Gross Pathology

Cirrhosis

Hepatocellular Carcinoma

Microscopic Pathology

Cirrhosis

Hepatocellular Carcinoma

References

  1. Nisini R, Paroli M, Accapezzato D, Bonino F, Rosina F, Santantonio T; et al. (1997). "Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles". J Virol. 71 (3): 2241–51. PMC 191332. PMID 9032359.
  2. 2.0 2.1 2.2 2.3 Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
  3. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D; et al. (2009). "Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene". J Gen Virol. 90 (Pt 11): 2759–67. doi:10.1099/vir.0.011239-0. PMID 19625466.
  4. Wedemeyer H, Manns MP (2010). "Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead". Nat Rev Gastroenterol Hepatol. 7 (1): 31–40. doi:10.1038/nrgastro.2009.205. PMID 20051970.
  5. World Health Organization. Global Alert Response. Hepatitis D 2001. http://www.who.int/csr/disease/hepatitis/whocdscsrncs20011/en/
  6. Shih HH, Shih C, Wang HW, Su CW, Sheen IJ, Wu JC (2010). "Pro-205 of large hepatitis delta antigen and Pro-62 of major hepatitis B surface antigen influence the assembly of different genotypes of hepatitis D virus". J Gen Virol. 91 (Pt 4): 1004–12. doi:10.1099/vir.0.017541-0. PMID 19940060.
  7. Shih HH, Jeng KS, Syu WJ, Huang YH, Su CW, Peng WL; et al. (2008). "Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus". J Virol. 82 (5): 2250–64. doi:10.1128/JVI.02155-07. PMC 2258943. PMID 18094179.
  8. Huang C, Chang SC, Yang HC, Chien CL, Chang MF (2009). "Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus". J Virol. 83 (23): 12314–24. doi:10.1128/JVI.01044-09. PMC 2786706. PMID 19793827.
  9. Wang YC, Huang CR, Chao M, Lo SJ (2009). "The C-terminal sequence of the large hepatitis delta antigen is variable but retains the ability to bind clathrin". Virol J. 6: 31. doi:10.1186/1743-422X-6-31. PMC 2661055. PMID 19284884.

Template:WH Template:WS